Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download
Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ADMA Biologics Inc (ADMA) vs Progressive Corp (PGR) Price & Performance

ADMA Biologics Inc
Progressive Corp

Price performance

Price movement over the last 24 hours

Key statistics

ADMA Biologics Inc vs Progressive Corp — how do they compare? ADMA Biologics Inc trades at $9.28 (market cap $2.13B), while Progressive Corp trades at $233.46 (market cap $136.47B). The key difference: Progressive Corp is far larger — about 64.1× ADMA Biologics Inc's market cap, and Progressive Corp pays a 5.93% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.

ADMAPGR
Market Cap
$2.13B$136.47B
Sector
HealthFinancials
52-Week High
$20.38$252.68
52-Week Low
$7.60$190.40
Enterprise Value
$2.20B$144.69B
Dividend Yield
5.93%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ADMA Biologics Inc

ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.

The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.

Progressive Corp

Progressive (PGR) trades at $234.40, up 0.94% with a bullish technical signal and strong fundamentals. Recent earnings beat expectations with Q1 2026 EPS of $4.96 versus $4.85 estimate, continuing a trend of operational strength. Revenue grew to $87.64B in 2025 with net income margin at 12.93%, while analyst consensus price target is $235.67. The stock shows resilience with positive media coverage highlighting earnings growth and leadership changes.

Outlook remains positive driven by earnings momentum and scale advantages in auto insurance. Key risks include competitive pressures and macroeconomic sensitivity. Institutional sentiment is mixed with 41.46% buy ratings, but the stock's valuation at P/E 11.78 offers room for upside if earnings trends persist.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ADMA Biologics Inc

ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.

Read more on ADMA

About Progressive Corp

Progressive underwrites private and commercial auto insurance and specialty lines

Read more on PGR